CSL Blames Since-Fixed Production Process For Fluvax Adverse Events
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL concluded after a four-year investigation of adverse events in children vaccinated with its influenza drug Fluvax that the company's manufacturing process, until recently still in use, was to blame.